Ki-67 antigen staining as an adjunct to identifying cervical intraepithelial neoplasia

被引:38
作者
Dunton, CJ
vanHoeven, KH
Kovatich, AJ
Oliver, RE
Scacheri, RQ
Cater, JR
Carlson, JA
机构
[1] THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107
[2] THOMAS JEFFERSON UNIV,DEPT ACAD COMP,PHILADELPHIA,PA 19107
关键词
D O I
10.1006/gyno.1996.4602
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of the work was to determine the feasibility and predictive value of Ki-67 immunostaining of cervical cytology and the detection of cervical dysplasia. Air-dried cervical smears were stained with MIB-1 antibody to identify the Ki-67 antigen. Nuclear decoration in abnormal squamous nuclei determined immunoreactivity. One hundred twenty-four nonpregnant patients underwent colposcopy and directed biopsies for abnormal cytology. Sensitivity (0.89), specificity (0.65), positive predictive value (0.60), and negative predictive value (0.91) were found for Ki-67 immunostaining in detection of high-grade cervical intraepithelial neoplasia (CIN) in 124 patients and positive Ki-67 staining was a significant predictor of high-grade CIN in both univariate (odds ratio 15.5 (95% CI 5.5-43.8) and multivariable (odds ratio 21.5 (95% CI 5.0-92.0) analysis. In 101 patients with ASCUS and LGSIL, Ki-67 immunostaining demonstrated the following in detection of high-grade CIN: sensitivity (0.96), specificity (0.67), positive predictive value (0.49), and negative predictive value (0.98). Ki-67 immunostaining of cervical cytology is a predictor of significant cervical pathology with high sensitivity and negative predictive value. Ki-67 immunostaining of cervical cytology may represent a new and cost-effective triage tool for patients with minor abnormalities on cytology. (C) 1997 Academic Press.
引用
收藏
页码:451 / 455
页数:5
相关论文
共 29 条
[11]  
KONISHI I, 1991, CANCER-AM CANCER SOC, V68, P1340, DOI 10.1002/1097-0142(19910915)68:6<1340::AID-CNCR2820680626>3.0.CO
[12]  
2-Q
[13]   INTERIM GUIDELINES FOR MANAGEMENT OF ABNORMAL CERVICAL CYTOLOGY [J].
KURMAN, RJ ;
HENSON, DE ;
HERBST, AL ;
NOLLER, KL ;
SCHIFFMAN, MH ;
BONFIGLIO, T ;
BUCK, H ;
CRUM, C ;
CURTIN, JP ;
GREENBERG, M ;
HATCH, K ;
JENSON, AB ;
JOHNSON, P ;
JONES, H ;
KAMINETSKY, H ;
KLEIN, L ;
KOSS, L ;
KRUMHOLZ, B ;
LEE, N ;
LUFF, R ;
MANDELBLATT, J ;
REID, R ;
RICHART, R ;
SEDLACEK, T ;
SNEIDERMAN, C ;
SOLOMON, D ;
STOLER, M ;
TAUB, F ;
TRIMBLE, E ;
TUCKER, E ;
TWIGGS, LB ;
WILKINSON, E ;
ATKINSON, B ;
AVERETTE, HE ;
CREASMAN, W ;
FRYHOFER, S ;
NOY, J ;
NIELSEN, M ;
NOLLER, K ;
PARK, R ;
WESTHOFF, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1866-1869
[14]  
MITTAL KR, 1990, ARCH PATHOL LAB MED, V114, P1038
[15]  
NAKANO T, 1991, CANCER, V68, P517, DOI 10.1002/1097-0142(19910801)68:3<517::AID-CNCR2820680312>3.0.CO
[16]  
2-9
[17]  
NAKANO T, 1993, CANCER, V72, P2401, DOI 10.1002/1097-0142(19931015)72:8<2401::AID-CNCR2820720818>3.0.CO
[18]  
2-D
[19]  
OKA K, 1993, CANCER, V72, P2621, DOI 10.1002/1097-0142(19931101)72:9<2621::AID-CNCR2820720917>3.0.CO
[20]  
2-E